Series B · Healthtech · Cambridge, United Kingdom · Founded 2018 · 60–100 employees
Cyted Health develops minimally invasive diagnostics for gastrointestinal diseases, specifically focusing on early detection of esophageal cancer and Barrett's esophagus. Their EndoSign capsule sponge device enables safe cell collection without endoscopy, offering a patient-friendly alternative that has already performed over 35,000 tests across the UK's National Health Service. The company recently secured $44 million in Series B funding to accelerate US expansion and has demonstrated significant clinical traction with FDA clearance for their diagnostic platform. Founded by University of Cambridge researchers including Professor Rebecca Fitzgerald, the company is transforming access to digestive health diagnostics globally.